Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-158
Official listed status: posted
Closing information: 2026-11-17 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Public and State controlled institutions of higher education; Private institutions of higher education; Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); Public housing authorities/Indian housing authorities; Native American tribal governments (Federally recognized); Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; Special district governments; For profit organizations other than small businesses; State governments
Federal synopsis
This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.